scholarly journals Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

2016 ◽  
Vol 17 (4) ◽  
pp. 452-463 ◽  
Author(s):  
Dong-Wan Kim ◽  
Ranee Mehra ◽  
Daniel S W Tan ◽  
Enriqueta Felip ◽  
Laura Q M Chow ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 1 Trial ◽  
Open Label Phase

scholarly journals Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 883-895 ◽  
Author(s):  
Scott J Antonia ◽  
José A López-Martin ◽  
Johanna Bendell ◽  
Patrick A Ott ◽  
Matthew Taylor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

2019 ◽  
Vol 7 (4) ◽  
pp. 347-357 ◽  
Author(s):  
Natasha B Leighl ◽  
Matthew D Hellmann ◽  
Rina Hui ◽  
Enric Carcereny ◽  
Enriqueta Felip ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 1 Study ◽  
Open Label Phase

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

2021 ◽  
Author(s):  
Justin F Gainor ◽  
Giuseppe Curigliano ◽  
Dong-Wan Kim ◽  
Dae Ho Lee ◽  
Benjamin Besse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

2016 ◽  
Vol 17 (12) ◽  
pp. 1683-1696 ◽  
Author(s):  
Scott N Gettinger ◽  
Lyudmila A Bazhenova ◽  
Corey J Langer ◽  
Ravi Salgia ◽  
Kathryn A Gold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 ◽  
Vol 14 (7) ◽  
pp. 590-598 ◽  
Author(s):  
Takashi Seto ◽  
Katsuyuki Kiura ◽  
Makoto Nishio ◽  
Kazuhiko Nakagawa ◽  
Makoto Maemondo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase

scholarly journals Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

2017 ◽  
Vol 18 (12) ◽  
pp. 1590-1599 ◽  
Author(s):  
Alice T Shaw ◽  
Enriqueta Felip ◽  
Todd M Bauer ◽  
Benjamin Besse ◽  
Alejandro Navarro ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 1 Trial ◽  
Ros1 Rearrangement
Sign in / Sign up

Export Citation Format

Share Document